Last Updated on October 17, 2024 by The Health Master
Zydus Cadila has received final approval from the USFDA to market Fluphenazine Hydrochloride Tablets in the strengths of 1 mg, 2.5 mg, 5 mg, and 10 mg (US RLD: Prolixin Tablets).
This medication is used to treat symptoms of a certain type of mental/mood condition (schizophrenia).
Fluphenazine belongs to a class of medications called phenothiazines and is also referred to as a neuroleptic.
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 318 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Other approvals:
Glenmark gets USFDA nod for Icatibant injection single-dose prefilled syringe
NATCO Pharma gets USFDA nod for Everolimus tablets
Natco Pharma gets USFDA nod for Lenalidomide capsules
Unichem Labs gets USFDA approval for Amitriptyline HCL Tablets
Alembic gets USFDA Final nod for Lurasidone HCL Tablets
Alembic gets USFDA nod for depression treatment drug
Also read:
Merck launches synthetic cholesterol product
Sun Pharma acquires trademarks of 3 diabetes drug from AstraZeneca
Draft guidelines issued for fee fixation for MBBS & PG courses
Govt constitutes National Council for Clinical Establishments
DCI issues advisory on holding examination by Dental colleges
Govt mandates deploying D Pharm, B Pharm & Pharm D in…
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
